ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 562

The Knock-Out Of TWEAK Receptor/Fn14 Ameliorates Lupus Nephritis In MRL/Lpr Mice

Yumin Xia1, Leal Herlitz2, Simona Gindea1, Jing Wen1, Rahul Pawar1, Alexander Misharin3, Harris R. Perlman4, Ping Wu5, Jennifer Michaelson5, Linda Burkly5 and Chaim Putterman6, 1Albert Einstein College of Medicine, Bronx, NY, 2The Department of Pathology, Columbia University Medical Center, New York, NY, 3Medicine, Division of Rheumatology, Northwestern University, Chicago, IL, 4Northwestern University, Chicago, IL, 5Biogen Idec, Cambridge, MA, 6The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: cytokines and lupus nephritis, SLE

  • Tweet
  • Email
  • Print
Session Information

Session Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Renal mesangial cells, podocytes, and tubular cells express Fn14, the sole confirmed receptor for the tumor necrosis factor (TNF)-family member cytokine TWEAK (TNF-like weak inducer of apoptosis). The activation of the TWEAK/Fn14 pathway induces kidney resident cells to produce multiple proinflammatory mediators as well as promotes their proliferation or death. In the chronic graft-versus-host and nephrotoxic serum models of antibody-mediated renal disease, we had previously found that genetic deficiency of Fn14, or treatment with an anti-TWEAK monoclonal antibody, decreases kidney inflammation and proteinuria without affecting systemic autoantibody titers. These studies suggest that inhibition of TWEAK/Fn14 interactions might be efficacious in the treatment of immune-mediated renal diseases. The purpose of this study was to evaluate the effect of Fn14 deficiency in spontaneous murine lupus nephritis (LN).

Methods:

Fn14-knock out (KO) 129 mice were backcrossed for eight generations onto MRL-lpr/lpr (wild type, WT) mice to generate MRL/lpr, Fn14 KO mice. Age and sex-matched MRL/lpr Fn14 WT littermates and MRL/MpJ mice were used as control strains. The severity of renal damage was evaluated by measuring proteinuria and renal function, and immunohistochemical staining of kidney tissues. Immunofluorescent microscopy and transmission electron microscopy (TEM) were performed on frozen kidney sections. The systemic effect of Fn14 KO was assessed by determining the levels of autoantibodies in sera, assessing lymphadenopathy, and analyzing splenocytes numbers and subsets.  

Results:

We found that at 26 to 38 weeks of age, female MRL/lpr Fn14-WT mice had significantly higher levels of proteinuria, BUN, and serum creatinine as compared to female Fn14-KO mice. Moreover, MRL/lpr Fn14 KO mice had significantly improved renal histopathology, with less glomerular immune deposition, endocapillary hypercellularity, mesangial proliferation, and perivascular inflammation. TEM revealed less electron-dense deposits and fusion of podocyte foot processes along the glomerular basement membrane of Fn14 KO mice. Furthermore, scoring of renal injury markers revealed diminished expression of Ki-67 and TIM-1 in the Fn14-KO mice, while immunofluorescence staining revealed reduced glomerular nephrin expression in the Fn14-WT mice. While the lymphadenopathy score was significantly improved in Fn14-KO mice, there were no differences between the strains in both autoantibody titers (anti-dsDNA, chromatin, ribosomal P, or cardiolipin IgG) at any time point between 26-38 weeks, or in splenocyte subsets at 38 weeks of age, suggesting that TWEAK likely acts by modulating events locally in the kidney.

Conclusion:

Our results demonstrate that the inhibition of TWEAK signaling by genetically deleting the Fn14 receptor significantly improved renal damage in spontaneous LN in MRL-lpr mice, suggesting that the TWEAK/Fn14 axis may be a novel therapeutic target for LN.


Disclosure:

Y. Xia,
None;

L. Herlitz,
None;

S. Gindea,
None;

J. Wen,
None;

R. Pawar,
None;

A. Misharin,
None;

H. R. Perlman,
None;

P. Wu,

Biogen Idec,

3;

J. Michaelson,

Biogen Idec,

3;

L. Burkly,

Biogen Idec,

3;

C. Putterman,

Biogen Idec,

2.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-knock-out-of-tweak-receptorfn14-ameliorates-lupus-nephritis-in-mrllpr-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences